American College of Clinical Pharmacy
      Search      Cart


Major Update to COVID-19 Treatment Guidelines Released

August 09, 2022

The COVID-19 Treatment Guidelines Panel (the Panel) has published an extensive update to the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Updates and changes include:

  • A new section entitled Special Considerations in People Who Are Immunocompromised. This section covers methods of preventing SARS-CoV-2 infection and discusses key considerations for clinicians managing patients with COVID-19 who are immunocompromised.
  • Three new sections that focus on the therapeutic management of COVID-19 in children: Pediatric Clinical Management Summary, Therapeutic Management of Nonhospitalized Children With COVID-19, and Therapeutic Management of Hospitalized Children With COVID-19.
  • Special Considerations in Children was revised to include recent epidemiologic data on COVID-19 and information on the risk factors for severe COVID-19 in children.
  • The Panel updated Prevention of SARS-CoV-2 Infection to include 2 new revisions to the Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for tixagevimab plus cilgavimab (Evusheld), including a warning about the potential risk of cross-hypersensitivity between COVID-19 vaccines and Evusheld and a new recommendation for repeat dosing of tixagevimab 300 mg plus cilgavimab 300 mg every 6 months, as authorized by the updated EUA.
  • Therapeutic Management of Nonhospitalized Adults With COVID-19 briefly discusses the recent case reports of viral rebound, with or without recurrence of symptoms, after a course of ritonavir-boosted nirmatrelvir (Paxlovid) has been completed. This section also reviews recent observational data showing that corticosteroids confer no benefits and may potentially cause harm in patients with COVID-19 who do not require supplemental oxygen.
  • An update to Kinase Inhibitors: Janus Kinase Inhibitors and Bruton’s Tyrosine Kinase Inhibitors references the recent approval of baricitinib by the FDA for the treatment of COVID-19 in hospitalized adults who require supplemental oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation. A new clinical data table summarizes the results of key randomized controlled trials.

For more information on these updates, please see What's New in the Guidelines on the COVID-19 Treatment Guidelines website.


This website uses cookies to help ACCP provide you with the best user experience. If you continue to use our services, ACCP will assume that you agree to the use of such cookies. You can find out how to update your settings by referring to ACCP’s Policy on Cookies.